May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Ocular Hypertension is More Common in Diabetic Macular Edema and Uveitis Than AMD Following Intravitreal Triamcinolone Acetonide Injection
Author Affiliations & Notes
  • P. Atmaca–Sonmez
    Ophthalmology, Kentucky Lions Eye Center, Louisville, KY
  • K. Sonmez
    Ophthalmology, Kentucky Lions Eye Center, Louisville, KY
  • C.C. Barr
    Ophthalmology, Kentucky Lions Eye Center, Louisville, KY
  • T.H. Tezel
    Ophthalmology, Kentucky Lions Eye Center, Louisville, KY
  • H.J. Kaplan
    Ophthalmology, Kentucky Lions Eye Center, Louisville, KY
  • Footnotes
    Commercial Relationships  P. Atmaca–Sonmez, None; K. Sonmez, None; C.C. Barr, None; T.H. Tezel, None; H.J. Kaplan, None.
  • Footnotes
    Support  Tubitak scholarship;Research to Prevent Blindness, New York; Kentucky Challenge Research Trust Fund.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3941. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Atmaca–Sonmez, K. Sonmez, C.C. Barr, T.H. Tezel, H.J. Kaplan; Ocular Hypertension is More Common in Diabetic Macular Edema and Uveitis Than AMD Following Intravitreal Triamcinolone Acetonide Injection . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3941.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the complications and associated risk factors after intravitreal triamcinolone acetonide (IVTA) injection. Methods: The charts of patients who had an IVTA injection and were regularly followed for a minimum of 3 months were reviewed. An association was sought between increased intraocular pressure (IOP) and age, sex, race, lens status (phakia vs pseudophakia), posterior capsule status (intact vs open), anterior chamber tap post–IVTA, prior treatment (trabeculectomy, vitrectomy), the type of diabetic retinopathy, glaucoma or ocular hypertension, and other possible risk factors. The characteristics of the IOP increase and the response of eyes to IVTA in bilaterally injected patients were also noted. Results: Fifty–one eyes of 49 patients with CNV secondary to AMD, 49 eyes of 40 patients with DME and 13 eyes of 12 patients with uveitis who had an IVTA injection were included in the study. 83% of eyes were followed–up for at least 6 months. Of the 113 eyes, 51 (45.1%) had an IOP greater than 21mmHg and 29 (25.7%) had greater than 25mmHg during the follow–up period. Young patients were more likely to experience an IOP increase (p=0.0001). An IOP increase occurred early in eyes with uveitis (mean 19.4 days), and late in eyes with DME (88.3 days). Eyes with AMD were the least likely to experience an increase in IOP (29.4%), compared to DME (59.2%) and uveitis (53.9%)(p=0.05). An open posterior capsule seemed to have a protective effect since 2 out of 13 eyes (15.4%) with an open posterior capsule and 20 pseudophakic eyes (47.6%) with an intact posterior capsule experienced an IOP increase (p=0.05). Sixteeen (14.2%) eyes developed a posterior subcapsular cataract; 1 eye, mild iritis; 1 aphakic eye, had TA enter the anterior chamber; 2 eyes, branch vein occlusion. Conclusions: Although IOP elevation after IVTA injection is common, it can usually be controlled medically. The IOP increase varied depending on the underlying disease and was worse for DME and uveitis compared to AMD. Young patients and eyes with an intact posterior capsule were under increased risk for developing IOP elevation.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • drug toxicity/drug effects • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×